MarketBeat
30 Jul 2026, 04:05 UTC · 2h ago
Glaukos Q2 Earnings Call Highlights
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
30 Jul 2026, 04:05 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Glaukos raised its full-year 2026 net sales guidance to a range of $680 million to $700 million, up from $620 million to $635 million. — A significant upward revision of annual revenue guidance typically triggers a positive re-rating of the stock price.
+0.80The iDose TR product contributed approximately $74 million to U.S. glaucoma revenue in Q2, with projected full-year 2026 revenue between $275 million and $280 million. — Strong commercial traction of a flagship product provides a concrete growth catalyst and validates the company's primary revenue driver.
+0.70The company's corneal health franchise grew 48% in Q2, driven by $11 million in Epioxa sales, with overall 2026 franchise growth projected at approximately 20%. — Diversification of revenue streams through successful new product launches reduces reliance on the glaucoma portfolio.
+0.50Continue reading
6 related stories
Top 3 movers · tap to explore
Gross margin for the second quarter was approximately 85%, with expectations for modest additional accretion through the remainder of 2026. — Expanding margins indicate improving operational efficiency and pricing power as higher-margin products gain share.
+0.30Management expects some volatility in third-quarter performance as Epioxa transitions to a permanent product-specific J-code. — Short-term billing and reimbursement volatility can create temporary headwinds for quarterly earnings reports.
-0.20Which stocks this story touches
The company reported record net sales, exceeded management expectations, and raised its full-year guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
WSJ
43m ago
